Peptides from frog skin with potential for development into agents for Type 2 diabetes therapy

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Several frog skin peptides, first identified as result of their antimicrobial or immunomodulatory activities, have subsequently been shown to stimulate insulin release both in vitro and in vivo and so show potential for development into incretin-based drugs for treatment of patients with Type 2 diabetes mellitus. However, their therapeutic potential as anti-diabetic agents is not confined to this activity as certain frog skin-derived peptides, such as magainin-AM2 and CPF-SE1 and analogs of hymenochirin-1B, tigerinin-1R, and esculentin-2CHa, have been shown to increase insulin sensitivity, promote β-cell proliferation, suppress pancreatic and circulating glucagon concentrations, improve the lipid profile, and selectively alter expression of genes involved in insulin secretion and action in mice with diet-induced obesity, insulin resistance and impaired glucose tolerance. This review assesses the therapeutic possibilities of peptides from frogs belonging to the Pipidae, Dicroglossidae, and Ranidae families, focusing upon work that has been carried out since 2014.
LanguageEnglish
Pages275-281
JournalPeptides
Volume100
DOIs
Publication statusAccepted/In press - 2 Sep 2017

Fingerprint

Medical problems
Anura
Type 2 Diabetes Mellitus
Skin
Insulin
Peptides
Pipidae
Insulin Resistance
Magainins
Ranidae
Incretins
Glucose Intolerance
Glucagon
Cell proliferation
Therapeutics
Nutrition
Obesity
Cell Proliferation
Diet
Lipids

Keywords

  • Host-defense peptide
  • frog skin
  • Type 2 diabetes
  • tigerinin
  • hymenochirin
  • esculentin-2
  • magainin
  • CPF

Cite this

@article{2ef253003d2241019426a808eea5427e,
title = "Peptides from frog skin with potential for development into agents for Type 2 diabetes therapy",
abstract = "Several frog skin peptides, first identified as result of their antimicrobial or immunomodulatory activities, have subsequently been shown to stimulate insulin release both in vitro and in vivo and so show potential for development into incretin-based drugs for treatment of patients with Type 2 diabetes mellitus. However, their therapeutic potential as anti-diabetic agents is not confined to this activity as certain frog skin-derived peptides, such as magainin-AM2 and CPF-SE1 and analogs of hymenochirin-1B, tigerinin-1R, and esculentin-2CHa, have been shown to increase insulin sensitivity, promote β-cell proliferation, suppress pancreatic and circulating glucagon concentrations, improve the lipid profile, and selectively alter expression of genes involved in insulin secretion and action in mice with diet-induced obesity, insulin resistance and impaired glucose tolerance. This review assesses the therapeutic possibilities of peptides from frogs belonging to the Pipidae, Dicroglossidae, and Ranidae families, focusing upon work that has been carried out since 2014.",
keywords = "Host-defense peptide, frog skin, Type 2 diabetes, tigerinin, hymenochirin, esculentin-2, magainin, CPF",
author = "JM Conlon and M Mechkarska and YHA Abdel-Wahab and Peter Flatt",
year = "2017",
month = "9",
day = "2",
doi = "10.1016/j.peptides.2017.09.001",
language = "English",
volume = "100",
pages = "275--281",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier",

}

Peptides from frog skin with potential for development into agents for Type 2 diabetes therapy. / Conlon, JM; Mechkarska, M; Abdel-Wahab, YHA; Flatt, Peter.

In: Peptides, Vol. 100, 02.09.2017, p. 275-281.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Peptides from frog skin with potential for development into agents for Type 2 diabetes therapy

AU - Conlon, JM

AU - Mechkarska, M

AU - Abdel-Wahab, YHA

AU - Flatt, Peter

PY - 2017/9/2

Y1 - 2017/9/2

N2 - Several frog skin peptides, first identified as result of their antimicrobial or immunomodulatory activities, have subsequently been shown to stimulate insulin release both in vitro and in vivo and so show potential for development into incretin-based drugs for treatment of patients with Type 2 diabetes mellitus. However, their therapeutic potential as anti-diabetic agents is not confined to this activity as certain frog skin-derived peptides, such as magainin-AM2 and CPF-SE1 and analogs of hymenochirin-1B, tigerinin-1R, and esculentin-2CHa, have been shown to increase insulin sensitivity, promote β-cell proliferation, suppress pancreatic and circulating glucagon concentrations, improve the lipid profile, and selectively alter expression of genes involved in insulin secretion and action in mice with diet-induced obesity, insulin resistance and impaired glucose tolerance. This review assesses the therapeutic possibilities of peptides from frogs belonging to the Pipidae, Dicroglossidae, and Ranidae families, focusing upon work that has been carried out since 2014.

AB - Several frog skin peptides, first identified as result of their antimicrobial or immunomodulatory activities, have subsequently been shown to stimulate insulin release both in vitro and in vivo and so show potential for development into incretin-based drugs for treatment of patients with Type 2 diabetes mellitus. However, their therapeutic potential as anti-diabetic agents is not confined to this activity as certain frog skin-derived peptides, such as magainin-AM2 and CPF-SE1 and analogs of hymenochirin-1B, tigerinin-1R, and esculentin-2CHa, have been shown to increase insulin sensitivity, promote β-cell proliferation, suppress pancreatic and circulating glucagon concentrations, improve the lipid profile, and selectively alter expression of genes involved in insulin secretion and action in mice with diet-induced obesity, insulin resistance and impaired glucose tolerance. This review assesses the therapeutic possibilities of peptides from frogs belonging to the Pipidae, Dicroglossidae, and Ranidae families, focusing upon work that has been carried out since 2014.

KW - Host-defense peptide

KW - frog skin

KW - Type 2 diabetes

KW - tigerinin

KW - hymenochirin

KW - esculentin-2

KW - magainin

KW - CPF

U2 - 10.1016/j.peptides.2017.09.001

DO - 10.1016/j.peptides.2017.09.001

M3 - Article

VL - 100

SP - 275

EP - 281

JO - Peptides

T2 - Peptides

JF - Peptides

SN - 0196-9781

ER -